Abstract New drugs with anti-tumor activity, also able to modify the expression of selected molecules, are under evaluation in breast cancer which is becoming resistant to conventional treatment, or in metastatic disease. The sodiumiodide symporter (NIS), which mediates iodide uptake into thyroid cells, and is the molecular basis of radioiodine imaging and therapy in thyroid cancer, is also expressed in a large portion of breast tumors. Since NIS expression in breast cancer is not sufficient for a significant iodide uptake, drugs able to induce its expression and correct function are under evaluation. In the present study, we report for the first time that the pan-deacetylase (DAC) inhibitor LBH589 (panobinostat) significantly induced NIS, both as mRNA and as protein, through the increase of NIS promoter activity, with the final consequence of obtaining a significant up-take of iodide in MCF7, T47D, and MDA-MB231 breast cancer cells. Moreover, we observed that LBH589 causes a significant reduction in cell viability of estrogen-sensitive and -insensitive breast cancer cells within nanomolar range. The anti-tumor effect of LBH589 is sustained by apoptosis induction and cell cycle arrest in G 2 /M. In conclusion, our data suggest that LBH589 might be a powerful tool in the management of breast cancer due to its multiple effects and support a potential application of LBH589 in the diagnosis and treatment of this disease.
Introduction
Breast cancer is the most common cancer in women all over the world [1] . Even though its management has become more and more successful over time, owing to the different available therapeutic strategies [2] , both metastatic disease and cancer which are becoming resistant to conventional treatment are emerging problems [3, 4] . New drugs with anti-tumor activity and/or able to modify the expression of selected molecules in these situations are under evaluation.
The sodium/iodide symporter (NIS) has been receiving a good deal of attention, both for its function that is requisite for potential clinical application, and for its sensitivity to a number of agents able to induce/increase its cell expression. NIS is a transmembrane glycoprotein mainly expressed in thyrocytes, functioning as iodide carrier [5] . The expression and correct functioning of NIS in differentiated thyroid cancer is the molecular requisite for successful radioiodide therapy in this neoplasm [6] . NIS is also expressed in lactating mammary glands, favouring iodide concentration in milk, and in more than 80% of human breast carcinomas [7] . Although NIS expression is present and intense in a majority of invasive breast cancers, radioiodide accumulation has been observed in only a small fraction of cases [8] [9] [10] . The achievement of a good level of expression of NIS is regarded as a promising new strategy to unable the use of radioiodide for imaging and treatment of breast cancer [11, 12] .
In non-neoplastic breast cells, estrogens, oxytocin, and prolactin, mainly acting in concert, were reported to induce NIS [7] . In breast cancer cells, many authors reported that retinoic acid is a powerful enhancer of NIS expression especially in association with corticosteroids [12] [13] [14] . Furthermore, in one report it was also observed that retinoic acid and dexamethasone treatment determined a significant 131 I-induced cytotoxicity in breast cancer cells [15] .
NIS expression, in both thyroid and non-thyroid cells, is also regulated by epigenetic phenomena. NIS gene silencing can be related to the level of histone acetylation; in fact, compounds like Trycostatin A (TSA), sodium butyrate (NaB), and valproic acid (VPA), that belong to the deacetylase inhibitor (DAC inhibitor) group, stimulate NIS expression in thyroid cancer cells [16] [17] [18] . DAC inhibitors [19, 20] could also be used to control NIS expression inducing radioiodine sensitivity in different human extrathyroid tumors such as breast cancer. Actually, it was reported that both TSA and NaB greatly increased NIS mRNA also in breast cancer MCF-7 cell line [21] .
The aim of the present work was to evaluate the ability of the powerful pan-DAC inhibitor LBH589 (panobinostat) [22] to induce the expression of functional NIS in breast cancer cells with different estrogen sensitivity.
Materials and methods

Cell lines and reagents
Estrogen receptor-positive MCF-7 and T47D and estrogen receptor-negative MDA-MB 231 cells were purchased from ECACC (Salisbury, UK).
Cells were routinely maintained at 37°C, in 5% CO 2 and 95% humidity, in RPMI 1640 (Sigma, St Louis, MO, USA) with 100 IU/ml penicillin and 100 lg/ml streptomycin added, supplemented with 10% heat-inactivated FCS (Euroclone, Wetherby, West York, UK).
LBH589 was provided by Novartis Pharma AG (Basel, Switzerland), prepared as a 5 mM stock solution in DMSO and stored at -20°C.
Immunoblotting
To evaluate the effect of LBH589 on histone H4 acetylation state, breast cancer cells, after treatment with LBH589 (5-100 nM), were harvested and lysed in the presence of 200 ll RIPA buffer (1% NP40, 0.5% desoxycholate sodium, 0.1% SDS in PBS pH 7.4, with 10 mg/ml PMSF, 30 ll/ml aprotinin, and 100 mM sodium orthovanadate) and incubated on ice for 30 min; cells were then centrifuged for 20 min at 15,0009g at 4°C, and clear supernatants used. SDS-PAGE was performed on gels, loading 40 lg protein/well. Separated proteins were electro-transferred onto PVDF membrane and probed with anti-acetylhistone H4 antibody (06-598, 1:1000 dilution, Upstate, Lake Placid, NY, USA). The membrane was then stripped and re-probed with an anti-GAPDH antibody (1:10000 dilution, Sigma, Saint Louis, MI, USA) to check protein loading. Proteins were detected with Pierce Super Signal chemiluminescent substrate following the manufacturer's instructions. Bands were photographed and analyzed using Kodak 1D Image Analysis software.
Cytotoxic activity
To evaluate the LBH589 cytotoxic activity, MCF-7, T47D, and MDA-MB 231 cells were seeded at 4 9 10 3 cells/well in 96-well plates (Corning, New York, NY, USA) in culture medium plus 10% heat-inactivated FCS. After 24 h, cells were exposed to increasing concentration of LBH589 (1-200 nM). After 72 h incubation cell viability was assessed using the Cell Proliferation Reagent WST-1 (Roche Applied Science, Penzberg, Germany), following manufacturer's instructions. Four replicate wells were used to determine each data point. Three response parameters, median growth inhibition (GI 50 ), total growth inhibition (TGI), and median lethal concentration (LC 50 ) were calculated for each cell line. The GI 50 corresponds to the concentration of the compound that inhibits 50% net cell growth; TGI value is the concentration of the compound leading to total growth inhibition; LC 50 value is the concentration of the compound leading to 50% net cell death.
Apoptosis detection-cell death detection ELISA For apoptosis studies, 4 9 10 3 cells were seeded in 96-well plates and treated with LBH589, using the same schedule as for the viability assay. After treatment, apoptosis was evaluated using Cell Death Detection ELISA PLUS (Roche Applied Science, Penzberg, Germany) following manufacturer's instructions. Apoptosis was expressed as enrichment factor, calculated as a fraction of the absorbance of treated cells versus untreated controls.
Cell cycle analysis
Cells were treated with LBH589 up to 72 h. At different times (24, 48 , and 72 h), all cells were collected, fixed in 70% ethanol for 30 min on ice, and incubated in propidium iodide solution (20 lg/ml propidium iodide, 0.2 mg/ml RNAseA in PBS) for 1 h at room temperature. The cell population was analyzed by flow cytometry.
Gene expression evaluation with real-time PCR Cells (1 9 10 6 ) were seeded in 75 cm 2 flasks and treated with LBH589 (5-100 nM).
Total RNA was extracted using TRIzol Reagent (Invitrogen Ltd, Paisley, UK), as previously described. DNase I was added to remove remaining genomic DNA. 1 lg of total RNA was reverse-transcribed with iScript cDNA Synthesis Kit (BioRad Laboratories, Inc.), following manufacturer's protocol.
Primers (Table 1) were designed using Beacon Designer 5.0 software according to parameters outlined in the BioRad iCycler Manual. Specificity of primers was confirmed by BLAST analysis. Real-time PCR was performed using a BioRad iQ iCycler Detection System (BioRad Laboratories, Inc.) with SYBR green fluorophore. Reactions were performed in a total volume of 25 ll, including 12.5 ll IQ SYBR Green Supermix (BioRad Laboratories, Inc.), 1 ll of each primer at 10 lM concentration, and 5 ll of the previously reverse-transcribed cDNA template. Protocol for primer set was optimized using seven serial 59 dilutions of template cDNA obtained from cells in basal conditions. The protocol used is as follows: denaturation (95°C for 5 min), amplification repeated 40 times (95°C for 15 s, 60°C for 1 min). A melting curve analysis was performed following every run to ensure a single amplified product for every reaction. All reactions were carried out at least three times for each sample.
Luciferase transcription assay Cells (2.5 9 10 5 ) were seeded in 6-well plates. 24 h after seeding, cells were transfected with 1 lg of NIS-luc plasmid/well using Lipofectin Reagent (Invitrogen Ltd, Paisley, UK). The plasmid, a kind gift of Prof. G. Damante (Dipartimento di Scienze and Tecnologie Biomediche, Policlinico Universitario di Udine, Udine) contains 2.2 kb of 5 0 genomic sequence for the NIS promoter and the minimal promoter is linked to the luciferase (LUC) gene as reporter [23] . After 24 h, cells were treated with LBH589 (10-50 nM) for a further 24 h. At completion, luciferase activity was assayed with the Luciferase Assay System (Promega Corporation, Madison, WI, USA).
NIS immunofluorescence microscopy Cells (5 9 10 5 ) were seeded in 6-well plates. 24 h after seeding, cells were treated with 25 nM LBH589 for 48 h. After treatment, cells were fixed in acetone/methanol (1:1) at -20°C for 20 min, washed with PBS containing 0.5% Triton X-100, 0.05% NaN 3 , and 1% Horse Serum and incubated with monoclonal anti-NIS antibody (1:1000) (FP5A, Thermo Fisher Scientific, Fremont CA, USA) in PBS at 4°C overnight. Then cells were washed with PBS containing 0.5% Triton and 0.05% NaN 3 for 10 min for three times followed by detection with anti-mouse Cy3-conjugated secondary antibody (1:1000), (GE Healthcare Europe, GmbH, Milano, Italy) in PBS plus 0.5% Triton and 0.05% NaN 3 for 2 h and nuclei counterstaining with Hoechst 33258 (500 ng/ml in DMSO) in PBS. Cells were washed twice with distilled water and mounted with 50% glycerol-PBS media.
125 I uptake by cells Cells (2 9 10 4 ) were seeded into 24-well plates and incubated with LBH589 (5-100 nM) for 48 h.
125
I uptake was assayed as reported elsewhere [18] . Briefly, after aspirating drug-containing medium, cells were washed with 1 ml HBSS (Invitrogen, Groningen, The Netherlands).
125 I uptake was initiated by adding 0.5 ml HBSS containing 2 lCi carrier-free Na 125 I (PerkinElmer Life and Analytical Sciences, Inc., Boston, USA) and 30 lM NaI. Incubation was conducted for 30 min at 37°C and terminated by removing the radioactive medium and washing the cells twice with ice-cold HBSS. Cells were then solubilized with 1 ml of absolute ethanol for 20 min, after which cell-associated iodide was measured in a c-counter.
Statistical analysis
Data are expressed throughout as means ± SEM, calculated from at least three different experiments. Comparison between groups was performed with analysis of variance (one-way ANOVA) and the threshold of significance was calculated with the Bonferroni test. Statistical significance was set at P \ 0.05.
Results
Anti-tumor activity of LBH589
LBH589 acts as deacetylase inhibitor (DAC inhibitor) in breast cancer cells, inducing hyper-acetylation of histone H4, as reported in Fig. 1 , and is a powerful cytotoxic agent causing a significant reduction in cell viability of MCF7, T47D, and MDA-MB231 cells (Fig. 2) . Furthermore, in Fig. 2 we report the calculated values of GI 50 , TGI, LC 50 that are all in nanomolar range. The mechanisms of action elicited by LBH589 to exert its cytotoxic activity in breast cancer cells are reported in Fig. 3 . Actually, LBH589 was able to induce apoptosis in a dose-dependent manner (panels on the left), and a significant growth arrest in G 2 /M (panels on the right). These effects were observed both in ER-positive and ER-negative breast cancer cells, even though higher doses of LBH589 were required in MDA-MB 231.
Effect of LBH589 on NIS expression and function
The ability of LBH589 to induce the Na ? /I symporter in breast cancer cells was thoroughly evaluated.
NIS was first studied as mRNA expression. As reported in Fig. 4 (panels on the left), the expression of NIS mRNA was significantly induced by LBH589 in a dose-dependent manner in all the three breast cancer cell lines. In addition, in Fig. 4 (panels on the right) we report the effect of LBH589 on the activity of NIS promoter, evaluated with a luciferase assay, demonstrating that LBH589 is effective in inducing NIS promoter activity in the cell lines under study.
The induction of NIS gene transcription has to go together with the presence of NIS protein in cells, and this was clearly demonstrated in MCF7, T47D, and MDA-MB231 breast cancer cells under LBH589 treatment as shown in Fig. 5 (upper panels) . Moreover, the symporter induced by LBH589 confers the ability of up-taking iodide to breast cancer cells (Fig. 5, lower panels) .
In all these experiments, LBH589 was effective in inducing a functional NIS either in ER-positive and ERnegative breast cancer cells, even though ER-positive cells were shown to be more sensitive to the compound.
Discussion
The present study shows the potent cytotoxic activity of LBH589 in both estrogen-sensitive and -insensitive cells and, especially, highlights its ability to induce the sodium/ iodide symporter (NIS) in breast cancer cells that, as a consequence, become able to concentrate radioactive iodide.
At present four different trials are recruiting patients with recurrent or metastatic breast cancer for treatment with LBH589 both in monotherapy and in association with trastuzumab and paclitaxel (www.clinicaltrials.gov), although knowledge concerning the precise mechanism of LBH589 cytotoxicity in breast cancer cells is still incomplete. The primary molecular effect of DAC inhibitors is to alter the acetylation status of the core histone proteins, facilitating chromatin remodelling, and modification in gene expression [24] . It has been reported that 100 and 200 nM LBH589 alone or in association with 4OHTam-oxifene were effective in reducing the growth of ER-negative MDA-MB 231cells [25] and that LBH589 significantly reduced the viability of ER-positive MCF-7 cells [26] and increased the fraction of dying cells after radiation exposure [27] . Here we demonstrate that LBH589 alone, in nanomolar range which is far from toxic range in humans [28] , is able to reduce the viability of ER-positive MCF-7 and T47D and ER-negative MDA-MB 231 breast cancer cells. Besides this, we show that the mechanisms underlying its effect on cell viability include both apoptosis induction and cell cycle arrest, as already reported for other DAC inhibitors [29] .
We demonstrate in particular that LBH589 induces and enhances NIS expression in breast cancer cells. The efficiency of NIS is at the basis of successful treatment of differentiated thyroid cancer thus the possibility of increasing NIS expression in thyroid neoplasms which have lost the ability to uptake and concentrate iodide is under extensive evaluation [30, 31] . Similarly, as NIS is expressed in quite a significant percentage of breast cancers [7] , NIS-mediated radionuclide imaging and targeted therapy could be useful goals in breast cancer management. Unfortunately, although NIS expression is present and intense in the majority of invasive breast cancers, only a small fraction of NIS-positive breast cancers is able to concentrate iodide, due to low cell surface NIS levels and cell surface trafficking defects, commonly found in breast tumors [32] . Therefore, research efforts should focus on strategies to induce/increase NIS expression in breast cancer as it has to be adequately expressed in order to get a considerable iodide uptake. A large number of agents with very different mechanisms of action have been utilized to stimulate NIS expression, such as re-differentiating agents [12, 15, [33] [34] [35] , or compounds that are reported to physiologically regulate NIS in breast cells [7, [36] [37] [38] . Retinoid acid, especially in the presence of other compounds such as dexamethasone, induces NIS and iodide uptake in breast cancer cells [12, 15, [33] [34] [35] and in animal models [39] . Even though these findings suggest their potential clinical use, as yet no clinical trials have been presently designed to this aim and additional strategies can be foreseen.
Epigenetic modifications, such as histone deacetylation, have been considered possible causes of NIS silencing in cancer cells. Our data clearly demonstrate that the deacetylase inhibitor LBH589 induced NIS, both as mRNA and as a protein, and determined a significant iodide uptake in breast cancer cell lines. Furthermore, the observation that LBH589 strongly activates the transcription of the construct luc-NIS that we had transfected in breast cancer cells both ER-positive (MCF-7 and T47D) and -negative (MDA-MB 231) is consistent with a direct effect of the drug on NIS promoter. Our data suggest that DAC-inhibitor treatment could therefore modify the acetylation state of NIS promoter allowing its transcription and expression as Fig. 4 LBH589 effect on NIS mRNA expression and NIS promoter activity. Left panels NIS mRNA was evaluated with real-time PCR in MCF-7, T47D, and MDA-MB 231 cells treated with 5-100 nM LBH589. Results were normalized for three different housekeeping genes (b-actin, b2-microglobulin, and L13A) and expressed as relative expression fold vs. untreated controls (0). Results are expressed as means ± SEM; n = 3. Right panels Breast cancer cells were transiently transfected with a reporter plasmid carrying the luciferase gene under the control of NIS promoter (NISluc). The luciferase activity was assayed before and after treatment with 10-50 nM LBH589. Data are expressed as mean ± SEM; n = 3 already reported for other DAC inhibitors 19]. The effect was evident regardless of ER status; even if both ER-positive MCF-7 and T47D cells are more sensitive than ER-negative MDA-MB 231 cells (the increase in NIS expression in ER-positive cells was about three times higher than in ER-negative cells). Thus, our study is the first report concerning the possibility to induce not only NIS mRNA expression but also iodide accumulation in breast cancer cells by using the pan-DAC inhibitor, LBH589.
In conclusion, the pan-DAC inhibitor LBH589 is a powerful anti-tumor agent and is able to induce NIS and iodide accumulation in breast cancer cells. The effects of LBH589 are independent from estrogen sensitivity and ERa-status of cells, making the drug of valuable use for diagnostic and therapeutic application in both estrogensensitive and -insensitive tumors. 
